



STATE OF IOWA

THOMAS J. VILSACK, GOVERNOR
SALLY J. PEDERSON, LT. GOVERNOR

DEPARTMENT OF HUMAN SERVICES
KEVIN W. CONCANNON, DIRECTOR

Iowa Medicaid Pharmaceutical and Therapeutics (P & T) Committee Meeting

March 9, 2006

Location: Room 116
State Capitol
Des Moines, Iowa

Time: 9:30 a.m. - 4:30 p.m.

AGENDA

1. Welcome & Introductions
 - a) Committee Members
 - b) Staff
2. Approval of the minutes
3. Update
 - a) Legislation
 - b) Preferred Drug List (PDL)
 - c) Prior Authorization Criteria
4. Public Comment (**See attachment 1 for Conflict of Interest Disclosure**)
5. Prior Economic Review of the Iowa Medicaid Preferred Drug List, Newly Released Drugs and Newly Released Generic Drugs, and New Dosage Forms (Closed Executive Session)
6. Preferred Drug List (PDL) discussion and deliberation
(**See attachment 2 for order of discussion**)
7. Final Recommendations by the P & T Committee on the Iowa Medicaid Preferred Drug List
Lunch Break 12:15 p.m.-1:00 p.m.
8. Review of Newly Released Drugs by Dr. Thomas Kline
(**See attachment 3 for order of discussion**)
9. Final Recommendations by the P & T Committee on Newly Released Drugs (Open Session)
10. Review of Newly Released Generics drugs by Dr. Tim Clifford
(**See attachment 4 for order of discussion**)
11. Final Recommendations by the P & T Committee on Newly Released Generic Drugs (Open Session)

Disclaimer: Executive Sessions may be necessary during the deliberation process

www.iowaMedicaidPDL.com

For more information contact Sandy Pranger at spranger@ghsinc.com or (515) 725-1272

IOWA MEDICAID ENTERPRISE - 100 ARMY POST ROAD - DES MOINES, IA 50315

Attachment 1
State of Iowa
Conflict of Interest Disclosure

The Iowa Medicaid Pharmaceutical and Therapeutics (P&T) Committee and persons testifying or presenting to the Iowa Medicaid P&T Committee are asked to disclose any financial or other affiliation with organizations that may have a direct or indirect interest in the business in front of the Committee.

A financial interest may include, but is not limited to, being a shareholder in the organization; being on retainer with the organization; or having research or honoraria paid by the organization.

An affiliation may include holding a position on an advisory committee or some other role or benefit to a supporting organization.

The existence of such relationships does not necessarily constitute a conflict of interest and will not preclude an individual from participating on, or addressing the P&T Committee. This policy is intended to openly identify any potential conflicts so that the P&T Committee members and the public are able to form their own judgments.

Please check the box of the statement that best applies.

Statement of No Conflicts

I do not have a current or recent (within the last 12 months) financial arrangement or affiliation with any organization that may have a direct interest in the business before the Iowa Medicaid P&T Committee.

Disclosures

I have a financial interest, affiliation or am employed by an organization that may have a direct interest in the business before the Iowa Medicaid P&T Committee

I refuse to state my affiliations

Organization	Role/Relationship

_____ (print name)

_____ (signature) (date)

Attachment 2
Iowa Medicaid Preferred Drug List

1. Cough and Cold Products

- Antitussive – Narcotic
- Antitussive – Non-Narcotic
- Antitussive – Expectorant
- Antitussive – Expectorant – Decongest – Antihist
- Antitussive – Expectorant – Decongestant
- Decongestant & Anticholinergic
- Decongestant & Antihistamine
- Decongestant w/Expectorant
- Decongestant – Antihistamine w/Expectorant
- Decongestant – Antihistamine – Anticholinergic
- Expectorant Mixtures
- Expectorants
- Narcotic Antitussive – Antihistamine
- Narcotic Antitussive – Decongestant
- Narcotic Antitussive – Decongestant – Antihistamine
- Non-Narc Antitussive – Antihistamine
- Non-Narc Antitussive – Decongestant
- Non-Narc Antitussive – Decongestant – Antihistamine
- Systemic Decongestants
- Topical Decongestants

2. Amaryl

3. Arava

4. Nevanac

5. Polyethylene Glycol (PEG)

6. Pletal

7. Retrovir

8. Vytarin

9. Xibrom

Attachment 3
Newly Released Drugs

1. Aczone
2. Angeliq
3. Arranon Injection
4. Avandaryl
5. Exjade
6. Flexbumin
7. Glumetza
8. Increlex
9. iPlex
10. Levemir
11. Nexavar
12. Orencia
13. Proquin XR
14. Synera

Attachment 4
Newly Released Generic Drugs

1. Azithromycin (generic Zithromax)
2. Ceftriaxone (generic Rocephin)
3. Danoxol (generic Danocrine)
4. Gatifloxacin (generic Tequin)
5. Glimepiride (generic Amaryl)
6. Levofloxacin (generic Levaquin)
7. Leflunomide (generic Arava)
8. Mupirocin Ointment (generic Bactroban Ointment)
9. Ondansetron (generic Zofran)
10. Oxybutynin ER (generic Ditropan XL)
11. Terbinafine (generic Lamisil)
12. Topiramate (generic Topamax)
13. Zidovudine (generic Retrovir)
14. Zonisamide (generic Zonegran)

New Dosage Forms and Strengths

1. Axid Oral Solution
2. Citalopram ODT
3. Clozapine 200mg
4. Kaletra tablets
5. Mobic Oral Suspension
6. Tramadol Extended Release
7. Xopenex HFA